天演药业上涨2.55%，报2.01美元/股，总市值9473.39万美元

Core Insights - Tianyan Pharmaceutical (ADAG) opened with a 2.55% increase, trading at $2.01 per share, with a total market capitalization of $94.73 million [1] - The company's total revenue for the year ending December 31, 2024, is reported at $103,200, reflecting a year-over-year decrease of 99.43% [1] - The net profit attributable to the parent company is reported at -$33.42 million, a decrease of 76.41% year-over-year [1] Company Overview - Tianyan Pharmaceutical is a platform-driven biopharmaceutical company focused on the development of clinical products, particularly in cancer immunotherapy [1] - The company utilizes a combination of computational biology and artificial intelligence to develop novel antibodies with high safety and efficacy [1] - The "Dynamic Precision Library" serves as the company's antibody discovery engine, driving the development of its product pipeline aimed at creating innovative or best-in-class products globally [1]